Evoke Neuroscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Evoke Neuroscience, founded in 2010 and based in New York, is a commercial-stage diagnostics company focused on cognitive health. Its core product is the FDA 510(k)-cleared Evoke System, which performs standardized EEG scans in a physician's office to generate reports aiding in the diagnosis of cognitive impairment. The company leverages a large, standardized EEG database and computational algorithms to provide objective neurophysiological biomarkers, targeting the massive and underserved market of early cognitive decline detection. Evoke operates a B2B model, selling its system directly to healthcare providers.

NeurologyCognitive ImpairmentDementia

Technology Platform

Integrated hardware/software system for quantitative EEG (qEEG) and event-related potential (ERP) acquisition and analysis. Uses computational algorithms to generate neurophysiological biomarkers from a large, standardized EEG database to aid in diagnosing cognitive impairment.

Opportunities

The aging global population and increasing prevalence of cognitive disorders create a massive, growing market for early detection tools.

The advent of disease-modifying Alzheimer's therapies increases the need for accurate, objective diagnostic aids in primary care settings.

The company's large, proprietary EEG database presents opportunities for high-margin data partnerships and algorithm licensing.

Risk Factors

Commercial adoption risk is high, as integrating a new device into primary care workflow is challenging and depends heavily on insurance reimbursement.

Competition from emerging blood-based biomarkers and other digital cognitive tools poses a threat.

Clinical utility must be continually proven to sustain physician use and secure favorable coverage policies.

Competitive Landscape

Evoke competes in the digital cognitive assessment space, which includes other qEEG/ERP-based devices, computerized neuropsychological testing platforms (e.g., CNS Vital Signs, Cogstate), and traditional paper-based tests. It differentiates with its FDA clearance for diagnosis aid, in-office hardware integration, and focus on physiological biomarkers rather than performance-based tasks. Long-term, it may face disruption from blood-based biomarkers currently in development.

More companies in Diagnostics & Precision Medicine →More companies in United States →